| Identification | Back Directory | [Name]
Dihydrostreptomycin | [CAS]
128-46-1 | [Synonyms]
DHSM
dhms
abiocine
vibriomycin
dihydro-streptomyci
DIHYDROSTREPTOMYCIN
DihydroestreptoMycin Sulfate
Benzimidazole, 2-cyanomethyl
dihydrostreptomycine sulphate
Dihydrostreptomycin USP/EP/BP
4)-N1,N3-bis(aMinoiMinoMethyl)-
Acetonitrile, 2-benzimidazolyl-
DihydrostreptomycineSulphateSterileUsp26
Dihydrostreptomycin (base and/or unspecified salts)
2)-O-5-deoxy-3-C-(hydroxyMethyl)-a-L-lyxofuranosyl-(1®
D-StreptaMine,O-2-deoxy-2-(MethylaMino)-a-L-glucopyranosyl-(1®
4-O-[2-O-[2-(Methylamino)-2-deoxy-α-L-glucopyranosyl]-5-deoxy-3-hydroxymethyl-α-L-lyxofuranosyl]-N,N'-bis(aminoiminomethyl)-D-streptamine
D-Streptamine, O-2-deoxy-2-(methylamino)-α-L-glucopyranosyl-(1→2)-O-5-deoxy-3-C-(hydroxymethyl)-α-L-lyxofuranosyl-(1→4)-N1,N3-bis(aminoiminomethyl)-
D-Streptamine, O-2-deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1?2)-O-5-deoxy-3-C-(hydroxymethyl)-.alpha.-L-lyxofuranosyl-(1?4)-N,N-bis(aminoiminomethyl)-
2-[(1S,3R,4S,5R,6R)-5-(Diaminomethylideneamino)-2-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-methylaminooxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-3,4,6-trihydroxycyclohexyl]guanidine
2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine | [EINECS(EC#)]
204-888-2 | [Molecular Formula]
C21H41N7O12 | [MDL Number]
MFCD00084778 | [MOL File]
128-46-1.mol | [Molecular Weight]
583.59 |
| Chemical Properties | Back Directory | [Melting point ]
>300 °C | [Boiling point ]
641.09°C (rough estimate) | [density ]
1.3963 (rough estimate) | [refractive index ]
1.6800 (estimate) | [pka]
pKa 7.8 (Uncertain) |
| Hazard Information | Back Directory | [Uses]
Antibacterial. | [Originator]
Dihydrostrepto,MSD ,US,1948 | [Definition]
ChEBI: Dihydrostreptomycin is a member of streptomycins. | [Manufacturing Process]
Dihydrostreptomycin sulfate may be prepared from streptomycin sulfate by
catalytic hydrogenation (Merck, Pfizer, Cyanamid), electrolytic reduction
(Schenley, Olin Mathieson), or by sodium borohydride reduction (Bristol), or
by isolation from a fermentation process (Takeda). | [Brand name]
Abocillin;Biostrep;Complexobiotico;Diapenin 3;Diapenin balsamico;Diarrestival;Didromycin;Didrothenate;Dihydrocidan sulfato;Dihydrostreptofar;Diidro-pantostrept;Distreptopab;Dreiciclina balsamica;Dst;Entera-strept;Estreptoluy;Estreptosirup;Helle-strep-forte;Hp 48;Mastigun;Mixtencillin;Retromyopen;Rocopenstrep;Sanstrepto;Solmycin;Solvo-strept;Streptoduocin;Veticar;Veycil-as. | [Therapeutic Function]
Antibiotic | [World Health Organization (WHO)]
Dihydrostreptomycin, a derivative of the aminoglycoside
antibiotic streptomycin with similar antibacterial activity, was first synthesized in
1947 and subsequently used in the treatment of tuberculosis and gram-negative
infections. Preparations for systemic use have been widely withdrawn as a result
of concern regarding their severe ototoxicity. Dihydrostreptomycin is poorly
absorbed from the gastrointestinal tract. It remains available in oral preparations in
some countries. |
| Safety Data | Back Directory | [Safety Profile]
Poison by intravenous
and intramuscular routes. Moderately toxic
by subcutaneous and intraperitoneal routes.
Human teratogenic effects by unspecified
route: developmental abnormahties of the
eye and ear. An experimental teratogen.
Other experimental reproductive effects.
Mutation data reported. A derivative of
streptomycin; has anesthetic properties.
When heated to decomposition it emits
toxic fumes of NOx |
|
|